Cleveland-based Athersys (NYSE:ATHX) has a full plate as it continues to advance its “off the shelf” stem cell therapy, MultiStem, through clinical trials in several indications. That means shareholders can expect more R&D spending and potential new partnerships this year as the company continues developing MultiStem and its 5HT2C agonist program. Athersys CEO Gil Van […]
It isn’t easy to get profit-hungry Wall Street excited about a drug that hasn’t yet been tested in humans and is at best years and years away from generating any sales, but Athersys (NASDAQ:ATHX) CEO Gil Van Bokkelen did his best in a recent conference call with investment analysts. That’s because there are recent signs […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Stem cell therapeutics developer Athersys’ (NASDAQ:ATHX) phase 2 clinical study investigating the treatment of inflammatory bowel disease with partner Pfizer (NYSE:PFE) is expected to complete patient enrollment by the end of 2012. Top-line results of the inflammatory bowel disease trial are likely to be available in early 2013, Athersys CEO Gil Van Bokkelen said in […]
Results of a preclinical study suggest that stem cell technology from Athersys (NASDAQ:ATHX) could offer a treatment for patients suffering from a rare disorder called “Hurler’s syndrome.” Hurler’s syndrome is a metabolic disorder in which patients produce too little of an enzyme that helps the body break down a complex type of sugar molecule found […]
Stem cell developer Athersys (NASDAQ:ATHX) has received a U.S patent that covers the use of nonembryonic, multipotent stem cells in the treatment of graft-versus-host disease. Graft-versus-host disease (GvHD) often occurs after a stem cell or bone marrow transplant in which the newly transplanted material attacks the transplant recipient’s body. The condition is often associated with […]
Gil Van Bokkelen, CEO of stem cell company Athersys (NASDAQ:ATHX), is typically one to speak in cautious and measured tones, but he made a brash statement in the company’s most recent quarterly earnings call. Van Bokkelen said Cleveland-based Athersys’ MultiStem stem cell therapy for ischemic stroke “could easily be one of the biggest blockbusters that […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Stem cell developer Athersys (NASDAQ:ATHX) has secured $9 million in a private placement with an unidentified investor. Cleveland-based Athersys said it would issue about 4.3 million shares of common stock and an equal number of warrants to purchase common shares at a price of $2.07. The warrants are exercisable for five years, according to a […]
Stem cell therapy developer Athersys (NASDAQ:ATHX) reported positive results from a phase 1 clinical trial in patients with leukemia and similar blood diseases. The trial showed that the company’s MultiStem technology may reduce the incidence and severity of graft-versus-host disease, according to a statement from Cleveland-based Athersys. Graft-versus-host disease (GvHD) often occurs after a stem […]
Stem cell developer Athersys (NASDAQ:ATHX) has received $3.6 million in new grant funding, with one of the grants going toward studying its MultiStem technology for the treatment of traumatic brain injury. A $1.9 million grant to study traumatic brain injury (TBI) comes from the National Institute of Neurological Disorders and Stroke, according to a statement […]
Athersys (NASDAQ:ATHX) has obtained a U.S. patent that covers the use of nonembryonic multi-potent stem cells for the treatment of several heart conditions, including heart attack. The patent provides protection for “multiple techniques” for delivering the stem cells to treat the conditions, which also include congestive heart failure and myocardial ischemia, according to a statement […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Athersys (Nasdaq:ATHX) has entered a partnership with a nonprofit multiple sclerosis group to investigate its adult stem cell technology for the treatment of MS. Fast Forward, a nonprofit subsidiary of the National Multiple Sclerosis Society, will commit up to $640,000 to fund animal studies of Athersys’ MultiStem in treating MS, a disease that attacks the […]
Stem cell developer Athersys (NASDAQ:ATHX) has taken the next of many steps toward commercializing its MultiStem therapy for stroke, the most promising application for the therapy. The Cleveland-based company detailed its plans for a phase 2 ischemic stroke clinical trial that’s estimated to involve about 140 patients, according to ClinicalTrials.gov, a website maintained by the […]
Stem cell therapy developer Athersys (NASDAQ:ATHX) plans to begin phase 2 clinical trials of its MultiStem therapy for stroke and heart attack patients by the end of the year. Moving ahead with its stroke therapy is key for Athersys because that application represents its biggest market. CEO Gil Van Bokkelen pegged the potential stroke market […]
As a small biotech with little revenue, no profits and no products on the market, stem cell therapy developer Athersys (NASDAQ:ATHX) is particularly vulnerable to big drops in its share price. That’s because Athersys’s primary method for raising cash is through direct offerings of its shares, such as an offering that raised $13 million for […]
Athersys (NASDAQ:ATHX) reported that results from a phase 1 trial of its stem cell therapy suggest its MultiStem technology could hold benefits for heart attack patients. The positive results from a one-year followup on the trial will pave the way for Cleveland-based Athersys to begin a phase 2 trial on heart attack patients later this […]